Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine-Reference-Cited by-同舟云学术

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

Published:2007-05 Issue:20 Volume:25 Page:4085-4092
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Catanzaro Andrew T.,Roederer Mario,Koup Richard A.,Bailer Robert T.,Enama Mary E.,Nason Martha C.,Martin Julie E.,Rucker Steve,Andrews Charla A.,Gomez Phillip L.,Mascola John R.,Nabel Gary J.,Graham Barney S.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference17 articles.

1. UNAIDS. Report on the Global AIDS Epidemic; 2006.

2. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine;Roy;Vaccine,2000

3. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine;Wang;Science,1998

4. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine;Graham;J Infect Dis,2006

5. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial;Martin;Clin Vaccine Immunol,2006

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial;Oncology Research and Treatment;2024

2. The dyeing effect of acridine orange for multiple plasmid systems is sensitive to temperature;Journal of Cellular Biochemistry;2023-11-27

3. Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?;Frontiers in Immunology;2023-01-09

4. A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization;2022-07-29

5. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529;Science;2022-04-22